

Organized by:



Hellenic and International Society of Molecular Targeted and Personalized Treatments (H.I.S.M.T.P.T.)
www.mtpt.gr



Young Oncologist Club Bulgaria

Under the auspice of:

- Hellenic Society of Medical Oncology
- Hellenic Society of Radiation Oncology
- Hellenic Society of Oral Oncology
- AKOS
- TAT

5-6 MAY
2017

H O T E L

DIVANI APOLLON
A T H E N S

12 CME – CPD points,
Panhellenic Medical Association

TAT 2017

THE HOME OF PHASE I IN ONCOLOGY

March 6-8, 2017

Paris,
France

4th

**Hellenic & Bulgarian
Congress**

with the subject:

**Immuno-Targeted
therapies** in solid

hematological
malignancies

& the **Highlights**

of the **15th TAT Congress 2017**



SCIENTIFIC PROGRAM



» Welcome from the Presidents

The Hellenic and International Society of Molecular-Targeted-Personalized Treatments and the Young Oncology Club-Bulgaria co-organise their **4th Congress** with the subject: «**Immuno-Targeted therapies in solid and hematological malignancies**» Rossitza Krasteva Ruseva, the President and her colleagues from Bulgaria, will present their experience -concerning the immuno-targeted therapies- in the field of basic research and clinical practice.

Dr. Vassili Soumelis from Curie Institute, Paris will present the recent data on immunotherapy and cancer.

The Professors in Medical-Oncology Dr. Giuseppe Giaccone (Georgetown University Washington DC, USA), and Jean-Pierre Armand (Institute Gustave Roussy, Paris) gave us the auspices to report the «highlights» from the 15th TAT (Targeted Anticancer Therapies) which was held in Paris (6-8 March 2017).

The «TAT Congress» is taking place one year in USA (Washington DC) and the other year in Europe(Paris) and presents all the International phase-I studies of the new molecules (immuno-targeted therapies in solid and hematological malignancies).

It is a great honor for our Societies to Co-organize the 4th Hellenic-Bulgarian Congress under the auspice of the TAT, and to report the highlights of «**TAT 2017**» from Paris in our Congress.

We welcome all of you in Kavouri - Athens - and wishing a fruitful Congress' attendance.

The Presidents of the Organizing Committee

Georgios Fotios Samelis MD
*President of the Hellenic-International
Society Molecular-Targeted
- Personalized Treatments*

Rossitza Krasteva Ruseva
*Head of Medical Oncology
Clinic Panagyuritsa
Chairman of Young Oncologist Club Bulgaria*

with the subject:

Immuno-Targeted therapies in solid hematological malignancies & the Highlights of the 15th TAT Congress 2017

► Commitees

ORGANIZING COMMITTEE

Honorary Members:	J.P. Armand G. Giaccone G. Zografos
President:	G.F. Samelis
Vice President:	Th. Giannaros
Gen. Secretary:	M. Konstantoulakis
Sp. Secretary:	P. Makrantonakis
Treasurer:	Sp. Volteas
Members:	K. Ekmektzoglou F. Zagouri

POSTER EVALUATING COMMITTEE

K. Ekmektzoglou
K. Chatzigiannakos
Th. Giannaros
G. F. Samelis
S. Volteas
F. Zagouri
E. Zografou

SCIENTIFIC COMMITTEE

President:	G. Zografos
Vice President:	P. Makrantonakis, G. F. Samelis
Members:	I. Adamopoulos G. Aravantinos J. P. Armand A. Ardavanis I. Athanasiadis V. Barbounis I. Drikos K. Ekmektzoglou K. Fragia V. Georgoulis G. Giaccone Th. Giannaros P. Ginopoulos S. Gouvalis Z. Kafiri D. Katsochi K. Konstantopoulos M. Konstantoulakis S. Kosmidis G. Koumakis R. Krasteva N. Malamos E. Michailakis I. Mountzios G. Nasioulas O. Nikolatou Galitis G. Papadopoulos S. Papadopoulos P. Papakostas G. Pissakas Ch. Poziopoulos A. Rebelakos E. Samantas V. Soumelis X. Vakalis I. Varthalitis M. Vaslamatzis S. Volteas F. Zagouri Z. Zahariev

► **SCIENTIFIC** PROGRAM

Friday 5th May 2017

10:00-11:00 Registrations

- 11:00-12:00 Immuno-Targeted Therapies in Hematological Malignancies**
Chair: **I. Adamopoulos, Ch. Poziopoulos, K. Konstantopoulos**
- 11:00-11:20 Targeted therapy with monoclonal antibodies **T. Vassilakopoulos**
11:20-11:40 Targeted therapy with small molecules **P. Tsirigotis**
11:40-12:00 Targeted cellular therapy **A. Spyridonidis**

- 12:00-13:00 Biomedical Research and Expertise**
Chair: **G. Nasioulas, I. Drikos, S. Kosmidis**
- 12:00-12:20 Molecular mechanism in genetic alterations and biomarkers of response in targeted drugs **I. Drikos**
12:20-12:40 Targeted the molecular pathway under the genomic profile of each patient **G. Nasioulas**
12:40-13:00 The evaluation of EGFR, ALK, KRAS, BRAF status in daily clinical therapeutic practice **E. Maragouli**

13:00-14:30 Break

- 14:30-15:30 Oral Complications in Patients, who Receive Targeted Therapies**
Chair: **O. Nicolatou Galitis**
- 14:30-14:40 BRAF inhibitors: Diffused white plaques of the oral cavity in a patient with melanoma receiving vemurafenib **E. Vardas**
14:40-14:50 Angiogenesis inhibitors: osteonecrosis of the jaw and metastatic disease in a patient with metastatic renal cell carcinoma receiving sunitinib, pazopanib and everolimus **E. Papadopoulou**
14:50-15:00 Angiogenesis inhibitors: gingival bleeding in a patient with metastatic renal cell carcinoma, receiving pazopanib **M. Kouri**
15:00-15:10 mTOR inhibitors: Aphthous-like ulcers in a patient receiving everolimus for endocrine tumor of unknown primary **X. Chatzihalepli**
15:10-15:20 Angiogenesis inhibitors: jaw pain and purulence in a patient with breast cancer, receiving bevacizumab and zoledronate **A. Vourli**
15:20-15:30 Discussion

with the subject:

Immuno-Targeted therapies in solid hematological malignancies & the **Highlights** of the 15th TAT Congress 2017

15:30-16:30	Immuno-Targeted Therapies in Kidney Cancer Chair: E. Michailakis, P. Ginopoulos, S. Gouvalis	
15:30-15:50	Molecular mechanisms involved in kidney cancer carcinogenesis	V. Melikoki
15:50-16:10	Molecular targeted therapies and therapeutic algorithm of administration (Sunitinib, Axitinib, Pazopanib, Everolimus, Nivolumab, etc)	G. Lainakis
16:10-16:30	Immunotherapy in kidney cancer	N. Tsoukalas
<hr/>		
16:30-17:45	Immuno-Targeted Therapies in Prostate Cancer Chair: A. Rebelakos, D. Katsochi, G. Aravantinos	
16:30-16:50	Molecular mechanisms involved in prostate cancer carcinogenesis	A. Dimitriadou
16:50-17:10	Radiotherapy at stage B – C	M. Trichas
17:10-17:30	Targeted therapies in hormone refractory prostate cancer (AbirateroneAcetate, Cabazitaxel, Enzalutamide, immunotherapy?)	S. Demiri
17:30-17:45	Targeting prostate cancer osteoblastic metastases by means of Nuclear Medicine approaches	V. Valsamaki
<hr/>		
17:45-18:00	Coffee Break	
<hr/>		
18:00-20:00	Young Oncology Club-Bulgaria: “Precision Medicine-Bulgarian Experience” Chair: R. Krasteva	
18:00-18:15	Beyond gene tests-advanced capabilities of molecular diagnostics	B. Petrov
18:15-18:30	Immunotherapy - New approach for the treatment of solid tumors-Bulgarian experience	A. Petrova/ T. Lubomirova
18:30-18:45	New opportunities for personalized treatment for lung cancer	N. Chilingirova
18:45-19:00	New opportunities for personalized treatment for breast cancer	M. Koleva/ R. Krasteva
19:00-19:15	Quality of life in women undergoing hormone therapy with early breast cancer	R. Krasteva
19:15-19:30	Clinical experience in Her-2 positive breast cancer	P. Balikova
19:30-19:45	Personalized treatment for primary multiplicity	H. Spasov
19:45-20:00	Discussion	

20:00-20:30 Coffee Break

20:30-21:00 **Opening Ceremony/ Welcome Addresses**

D. Katsochi

President of AKOS, Radiation Oncologist

O. Nikolatou Galitis

President of the Hellenic Society of Oral Oncology

X. Vakalis

On behalf of the Hellenic Society for Radiation Oncology

G. Aravantinos

Vice President of the Hellenic Society of Medical Oncology

G. Zografos

Honorary Members's Representative, Professor of Surgery,
Director of the 1st Surgical Department,
University of Athens, President of the Scientific Committee

R. Krasteva

Head of Medical Oncology Clinic
100 «G.Benkovski» str. Panagyurishte -4500 Bulgaria
Chairman of Young Oncologist Club Bulgaria, co - President
of the Organizing Committee

G. F. Samelis

President of the Organizing Committee,
President of the Hellenic-International Society Molecular-Targeted -
Personalized Treatments (H.I.S.M.T.P.T)

21:00-21:30 **Opening Ceremony Honorary Keynote Lecture**

Chair: **V. Georgoulis, G. Samelis**

Immunotherapy and cancer

Prof. V. Soumelis

21:30-23:00 **Welcome Reception**

with the subject:

Immuno-Targeted therapies in solid hematological malignancies & the **Highlights** of the 15th TAT Congress 2017

Saturday 6TH May 2017

08:30-09:00 Registrations

09:00-10:00 **Immuno-Targeted Therapies in Melanoma**

Chair: **K. Fragia, S. Papadopoulos.**

- 09:00-09:20 Immunotherapy (immune checkpoint inhibitors) in metastatic disease **F. Stavridi**
- 09:20-09:40 Targeted drugs after resistance effect in metastatic melanoma (Dobrafenib, Imatinib, Dasatinib, Nilatinib etc) **M. Tsigaridas**
- 09:40-10:00 Treatment of dermatological toxicity from targeted therapies (EGFR, TK inhibitor, Vemurafenib Ipilimumab) **M. Politou**

10:00-11:00 **Immuno-Targeted Therapies in Lung Cancer**

Chair: **E. Samantas, X. Vakalis, M. Vaslamatzis**

- 10:00-10:20 ALK +disease: 1st, 2nd, 3rd line treatments **M. Nikolaou**
- 10:20-10:40 Targeted the KRAS, EGFR, ALK, BRAF, ROS pathways **Sp. Papanikolaou**
- 10:40-11:00 The present-future of immunotherapy in Lung cancer **N. Kentepozidis**

11:00-11:30 Coffee Break

11:30-12:30 **Immuno-Targeted Therapies in Breast Cancer (A)**

Chair: **G. Zografos**

- 11:30-11:50 Targeted lumpectomy or targeted mastectomy **N. Michalopoulos**
- 11:50-12:10 Targeted Therapies in triple negative metastatic disease **M. Theohari**
- 12:10-12:30 New options of immunotherapy in breast cancer **A. Tzovas**

12:30-13:30 **Immuno-Targeted Therapies in Breast Cancer (B)**

Chair: **V. Barbounis, S. Kosmidis, A. Ardavanis**

- 12:30-12:50 Diagnostic approaches via classical or digital mammography **A. Nikita**
- 12:50-13:10 miRNAs in breast cancer **D. Kalapanida**
- 13:10-13:30 Targeted therapies in metastatic breast cancer (CDK4/6, P13K/AKT/mTOR inhibitors, NabPaclitaxel,erubilin) **F. Zagouri**

13:30-14:00 **Lecture**

Chair: **P. Makrantonakis, F. Zagouri**

The role of Trabectedin in gynecological cancer

D. Tzaninis

14:00-15:30 Lunch Break

15:30-16:30

Oral Presentations for Selected Posters for Awards

Chair: **S. Volteas, Th. Giannaros, K. Ekmektzoglou**

A1: Evaluation of Met – Polymorphisms in Patient with Triple Negative Breast Cancer

Despoina Kalapanida¹, Maria Gazouli⁴, George Samelis³,
Theodoris Sergeantanis¹, AndrianniTsiakou⁵, Adreas Makradonakis,
Eleni Zografou⁴, Constantinos Dimitrakakis², Aris Giannos²,
Spyros Marinopoulos², Eustathios Kastritis¹, EuaggelosTerpos¹,
Meletios-Athanasios Dimopoulos¹, Flora Zagouri¹

1. Department of clinical Therapeutic, Alexandra Hospital, Athens, Greece,

2. Department of Obstetrics and Gynaecology, Alexandra Hospital, University of Athens School of Medicine, Athens, Greece,

3. Oncology Department, Ippokratio Hospital, Athens, Greece,

4. Department of Basic Medical Sciences , Laboratory of Biology, University of Athens School of Medicine and Laboratory of Cell and Gene Therapy, Biomedical Research Foundation of the Academy of Athens , Athens , Greece,

5. First Department of Dermatology, Syggros Hospital, University of Athens School of Medicine, Athens, Greece

INTRODUCTION

Triple negative breast cancer constitutes 20% of breast cancer. Single Nucleotide Polymorphisms (SNPs) may signal areas that predispose to the development of breast cancer, even if they do not lead to the disease in the absence of other factor.

AIM

To evaluate the role of Met T1010I and rs40239 as a potential prognostic marker in patient with triple negative breast cancer who have received chemotherapy.

METHODS

Design of case-control study: Regarding breast cancer patients, 114 samples of DNA from paraffin embedded breast normal tissues was isolated with the Nucleopsin Tissue kit (Macherey Nigel, Germany). Concerning controls, 124 samples of DNA from blood was isolated with the same kit. Polymerase chainreactions (PCR) and ELIZA were used for the enhancement and further processing of the samples. Regarding the case-control study, logistic regression analysis was performed to examine whether the examined polymorphisms were associated with the risk of breast cancer. Multivariate Cox analysis was performed in the longitudinal study for the evaluation of associations between the polymorphisms and overall survival.

RESULTS

Met T1010I CT genotype was associated with increased risk of breast cancer (OR=3.88, 95%CI: 1.04-14.47, p=0.044, vs. CC); no T1010I TT subjects were identified either in cases or controls. On the other hand, rs40239 was not associated with breast cancer risk (OR=0.89, 95%CI: 0.52-1.50, p=0.652, AG and GG grouped together vs. AA). Neither T1010 (HR=1.35, 95%CI: 0.31-5.97, p=0.691, CT vs. CC) nor rs40239 (HR=1.78, 95%CI: 0.73-4.35, p=0.205, AG/GG vs. AA) were associated with overall survival of breast cancer.

CONCLUSION

Met T1010I CT genotype was associated with increased risk of TNBC whereas rs40239 was not associated with triple negative breast cancer risk.

with the subject:

Immuno-Targeted therapies in solid hematological malignancies & the Highlights of the 15th TAT Congress 2017

A2: Thromboprophylaxis during chemotherapy: preliminary results

Stefanidis J, Kypouris S, Bananis K, Adam S, Samelis G*, Volteas S.K.

Department of Surgery and Oncology, Hippocrates Hospital, Athens Greece*

A3: Neuroendocrine tumors of the small intestine

Stefanidis J, Adam S, Mouzaki Mary, Halatsis K, Hamzin A, Volteas S.K.

Department of Surgery, Hippocrates Hospital, Athens Greece

A4: Prophylactic mastectomy in hereditary breast cancer

Koutkia Christina, Mouzaki Mary, Bananis K, Varsos P, Adam S, Volteas S.K.

Department of Surgery, Hippocrates Hospital, Athens Greece

A5: A rare case of liver cystadenoma

Stefanidis J, Mpartsokas Ch, Karantzikos G, Hamzin A, Halatsis K,

Volteas S.K.

Department of Surgery, Hippocrates Hospital, Athens Greece

A6: Gallbladder cancer: current management strategies

Stefanidis J, Galateros G, Adam S, Varsos P, Kypouris S, Volteas S.K.

Department of Surgery, Hippocrates Hospital, Athens Greece

A7: Paraneoplastic syndrome of unknown origin-diagnostic considerations

Stefanidis J, Mattheou S, Konstantinidis Ch, Stroumpouli Evangelia,

Mpartsokas Ch, Karantzikos G, Volteas S.K

Department of Surgery, Hippocrates Hospital, Athens Greece

A8: The diagnostic value of internal examination of the rectum at the A&E department

Annousis K, Matalliotaki C, Andreadakis G, Kosta D, Mantelou A,

Koumentakis E, Dimitriadis E, Kounounas T, Andreadakis E, Moudatsakis N.

Department of Surgery, Agios Nikolaos Hospital, Crete Greece

A9: Large intestine and rectal cancer-Observations upon the surgical treatment

Andreadakis G, Annousis K, Matalliotaki C, Kosta D, Koumentakis E,

Dimitriadis E, Kounounas T, Andreadakis E, Moudatsakis N.

Department of Surgery, Agios Nikolaos Hospital, Crete Greece

A10: Non-melanoma skin cancer: the experience of a general surgery clinic

Kosta D, Annousis K, Matalliotaki C, Andreadakis G, Mantelou A,

Koumentakis E, Dimitriadis E, Kounounas T, Andreadakis E, Moudatsakis N.

Department of Surgery, Agios Nikolaos Hospital, Crete Greece

16:30-18:00	Targeted Therapies in Gastrointestinal Cancers Chair: P. Papakostas, M. Konstantoulakis, Z. Kafiri	
16:30-16:50	Molecular basis of carcinogenesis in gastrointestinal tumors	K. Ekmektzoglou
16:50-17:10	Whipple operation in pancreatic cancer (state of the art)	K. Bramis
17:10-17:30	Targeted therapies in left and right colon cancers through Kras, Nras, Braf status and the sequence of administration	E. Galani
17:30-18:00	Targeted therapies in stomach and pancreatic cancers (Teysono, Herceptin, ramucirumab, nabpaclitaxel, etc)	Th. Tegos

18:00-18:30 Coffee Break

18:30-19:30 **The Highlights of the 15th TAT Congress 2017 (Paris 6-8 March 2017)**
Chair: **J.P. Armand, G. Giaccone, G. Samelis**

18:30-18:50	G. Giaccone Georgetown University Washington DC	
18:50-19:10	J.P. Armand Institute Gustave Roussy Paris	
19:10-19:30	Discussion	

19:30-20:00 **Closing Ceremony Honorary Lecture**
Chair: **G. Samelis, G. Aravantinos**
Novel Treatments in Lung Cancer **Prof. G. Giaccone**

20:30 **End of the Congress**

with the subject:

Immuno-Targeted therapies in solid hematological malignancies & the Highlights of the 15th TAT Congress 2017

Speakers-chairpersons

- Adamopoulos I.** Hematologist, Director of Hematological Dept, G.H. Kalamata
- Aravantinos G.** MD, PhD, Consultant in Medical Oncology, Head, 2nd Dept of Medical Oncology, "Agiou Anargyri" Cancer Hospital
- Ardavanis A.** Medical Oncologist, Director of the 1st Department of Medical Oncology, Anticancer Hospital "Agios Savvas"
- Armand J.P.** Senior Consultant, Drug Development Dept (DITEP), Institut Gustave Roussy, Cancer Campus Grand Paris, France, Past ESMO President
- Barbounis V.** MD, PhD, Medical Oncologist, "Metropolitan" Hospital
- Balikova P.** MD, Medical Oncology Dept. University Hospital "Tsaritsa Joanna- ISUL" - Sofia
- Bramis K.** MD, PhD, MSc, General and Hepatobiliary Surgeon, 1st Department of Propaedeutic Clinic of University Medical School of Athens, "Hippokraton" General Hospital
- Chatzihalepli Ch.** DDS, Postgraduate student in Oral Pathobiology, Clinic of Hospital Dentistry, Dental School, National and Kapodistrian University of Athens, Greece
- Chilingirova N.** MD, Medical Oncology Dept. National Oncology Center Sofia
- Demiri S.** Consultant MD Oncologist, 2nd Dept. Anticancer Center "Saint Savvas"
- Dimitriadou A.** PhDc, Resident of Medical Oncology, "Evangelismos" Athens General Hospital
- Drikos I.** MD, PhD, Kapodistrian University of Athens Paediatric Resident - "Thriasio" General Hospital of Elefsina ex. "Aretaiion" University Hospital - Neonatal Department
- Ekmektzoglou K.** MD, PhD, Department of Gastroenterology, Army Share Fund Hospital (NIMTS), Athens, Greece
- Fragia K.** MD, Ph.D, Chief Pathologist, HistoBio Diagnosis [HBD] Pathology Laboratory
- Galani E.** MD, Medical Oncologist, Metropolitan Hospital
- Georgoulas V.** MD, PhD, Prof. Emer. of Medical Oncology, School of Medicine, University of Crete, Greece
- Giaccone G.** MD, PhD, Associate Director for Clinical Research, Lombardi Comprehensive Cancer Center Georgetown University, Washington DC, USA, Professor of Medical Oncology and Pharmacology
- Giannaros T.** Molecular & Nuclear Biologist, PhD rer. nat. MSc. rer. nat. Dr. phil.
- Ginopoulos P.** MD, PhD, Specialist in Internal Medicine & Clinical Oncology, Coordinator Chairman of Clinical Oncology Department, General Hospital "St Andreas", Patras, Greece
- Gouvalis S.** Urologist, DTCA Hygeia
- Kafiri G.** Pathologist, PhD, Director of the Pathology Dept, "Hippokraton" General Hospital Athens Greece
- Kalapanida D.** MD, Resident of Internal Medicine, Dept of Therapeutic, "Alexandra" Hospital, Athens, Greece
- Katsochi D.** Radiation Oncologist, DTCA Hygeia, Founder and Director of the Nonprofit Company "AKOS"

- Kentepozidis N.** Medical Oncologist, MD, PhD, Head of Oncology Clinic, "251" General Airforce Hospital
- Koleva M.** MD, Head of Medical Oncology Dept. University Hospital "Tsaritsa Joanna-ISUL" - Sofia
- Konstantopoulos K.** Professor of Hematology, Chairman, Dept of Hematology, Athens University, Medical School, "Laikon" General Hospital of Athens
- Konstantoulakis M.** Professor of Surgery, National and Kapodistrian University of Athens (NKUA), 1st Dept of Propaedeutic Surgery "Hippocratio" General Hospital of Athens
- Kosmidis S.** Assistant Professor of Medicine, Aristotle University of Thessaloniki
- Kouri M.** DDS, MSc, PhD Candidate in Oral Pathobiology, Clinic of Hospital Dentistry, Dental School, National and Kapodistrian University of Athens, Greece
- Krasteva R.** MD, Head of Medical oncology Hept. CBCCS / Central Bulgarian Comprehensive Cancer Services/ UNI Hospital - Panueristhe
- Lainakis G.** MD, Medical Oncologist, Athens Medical Center
- Lubomirova T.** MD, Medical Oncology Dept. Tokuda Hospital - Sofia
- Makrantonakis P.** MD, PhD, Medical Oncologist, Head of 2nd Dept of Clinical Oncology, Anticancer Hospital Thessaloniki "Theageio"
- Maragouli E.** Medical Oncologist, Oncology Dept of University Hospital in Larissa, Thessaly, Biologist of Aristotele University of Thessaloniki
- Melikoki V.** MD, Assistant of Oncology Dept, "Hippokratio" General Hospital of Athens
- Michailakis E.** Medical Oncologist
- Michalopoulos N.** MD, MSc, PhD, Surgeon, 1st Dept of Propaedeutic Surgery, University of Athens, Greece
- Nasioulas G.** PhD, Scientific Director Genekor
- Nikita A.** M.D, PhD, Consultant Breast Radiologist
- Nikolaou M.** MD, MSc, PhD, Medical Oncologist, Dept of Internal Medicine, "Hippokratio" General Hospital of Athens
- Nikolatu - Galitis O.** DDS, MSc, DrDent, Professor & Head Clinic of Hospital Dentistry & Dental Oncology Unit, Dental School, University of Athens
- Papadopoulos S.** MD, IFCAP, Pathologist, Head of Pathology Dept & Medical officer, "Hygeia" Hospital
- Papadopoulou E.** DDS, MSc, PhD Candidate in Oral Pathobiology, Clinic of Hospital Dentistry, Dental School, National and Kapodistrian University of Athens, Greece
- Papakostas P.** Medical Oncologist, Head of Oncology Unit, "Hippokratio" General Hospital of Athens
- Papanikolaou S.** MD Medical Oncologist, Consultant Medical Oncologist, "Iatriko" Palaiou Falirou
- Petrova A.** MD, Medical oncology - Sofia
- Petrova B.** MD, MBA General Manager
- Politou M.** Dermatologist Venereologist, Consultant at 1st University Clinic "A.Sygros"

with the subject:

Immuno-Targeted therapies in solid hematological malignancies **& the Highlights of the 15th TAT Congress 2017**

- Poziopoulos Ch.** Hospital
MD - Haematologist - Head of Haematology Unit, "Metropolitan" Hospital, N. Faliro
- Rebelakos A.** Consultant Urologist
- Samantas E.** MD, PHD Director, 3rd Oncology Dept, "Agii Anargiri" Cancer Hospital
- Samelis G.** Medical Oncologist, Director of Oncology Unit, "Hippokratio" General Hospital of Athens, President of the Hellenic-International Society Molecular-Targeted - Personalized Treatments (H.I.S.M.T.P.T)
- Sapsov H.** MD, Medical oncology SERDIKA Hospital Sofia
- Soumelis V.** MD, PhD, Senior Physician and Team Leader, Department of Immunology Institut Curie, Paris, France
- Spiridonidis A.** MD, PhD, Director of the Bone Marrow Transplantation Unit, Director of CBMDP (Donor Registry GR2), President, BMT WP of Hellenic Society Haematology Hellenic Representative in EU Commission "Tissues and Cells" University of Patras
- Stavridi F.** MD, MSc, MRCP, Medical Oncologist, Consultant in Medical Oncology, "Hygeia" Hospital
- Tegos Th.** Medical Oncologist, Phdc
- Theohari M.** MD, Medical Oncology Consultant "Hippokratio" University Oncology Unit
- Trichas M.** Radiation Oncologist, "Iaso" Hospital
- Tsigaridas K.** Medical Oncologist, Oncology Dept, "Metropolitan" Hospital
- Tsirigotis P.** Assistant Professor in Hematology, National and Kapodistrian University of Athens
- Tsoukalas N.** MD, MSc, PhD, Medical Oncologist, MSc in Bioinformatics, Consultant at Veterans Hospital (NIMTS)
- Tzanninis D.** MD, Medical Oncologist, Head of Oncology Unit, Athens Medical Center
- Tzovaras A.** Medical Oncologist, PhD, "Henry Dunant" hospital
- Vakalis X.** Radiation Oncologist, Dept of Radiation Oncology/ Medical Center of Athens
- Valsamaki P.** MD, PhD, Nuclear Physician, Consultant Nuclear Medicine Department, University General Hospital "Alexandra"
- Vardas E.** DDS, MSc, Dr Dent, Scientific Associate, Clinic of Hospital Dentistry, Dental School, National and Kapodistrian University of Athens, Greece
- Vaslamatzis M.** MD, PhD, Head of the Department of Medical Oncology, "Evangelismos" General Hospital, Athens Hellas
- Vassilakopoulos Th.** Assistant Professor of Hematology, Hematology Clinic UOA, General Hospital of Athens "Laiko"
- Volteas S.** MD, PhD, Consultant General Surgeon
- Vourli A.** DDS, MSc, Clinic of Hospital Dentistry, Dental School, National and Kapodistrian University of Athens, Greece
- Zagouri F.** MD, PhD, Medical Oncologist, "Alexandra" Hospital, University of Athens
- Zografos G.** MD, PhD, F.A.C.S., Professor of Surgery, Vice Rector, National and Kapodistrian University of Athens (NKUA), Chairman of 1st Dept of Propaedeutic Surgery "Hippokratio" General Hospital of Athens

➤ General informations

Organized by

- Hellenic and International Society of Molecular Targeted - Personalized Treatments (H.I.S.M.T.P.T.)
- Young Oncologist Club Bulgaria

Under the auspice of



Congress Dates

May 5th & 6th, 2017

Congress Venue

Divani Apollon Hotel
Ag. Nikolaou 10, Vouliagmeni,
Athens, 166 71, Greece,
Tel. 21 0891 1100

Language

The official language of the congress is English.

Registration

No Congress Registration fees applied

Certificate of Attendance

All registered participants who have attended at least 60% of the total scientific program will receive a certificate of attendance from the secretariat desk after the closing ceremony.

Congress Secretariat



E.T.S. Events & Travel Solutions S.A.
154 El. Venizelou Str. 171 22 N. Smirni, Athens-Greece
Tel: +30 210 98 80 032, Fax: +30 210 98 81 303
E-mail: ets@otenet.gr ets@events.gr • Website: www.events.gr